Trial Profile
A Phase I Study of CX5461
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Aug 2023
Price :
$35
*
At a glance
- Drugs Pidnarulex (Primary)
- Indications Advanced breast cancer; Male breast cancer; Solid tumours
- Focus Adverse reactions
- 18 Jan 2023 Status changed from active, no longer recruiting to completed.
- 13 Jun 2022 Planned End Date changed from 30 Apr 2022 to 30 Dec 2022.
- 10 Jan 2022 Planned End Date changed from 31 Jan 2022 to 30 Apr 2022.